Roche’s Tecentriq Shows Survival In Triple-Negative Breast Cancer, For Some
Treatment with Tecentriq helped some patients with aggressive metastatic triple-negative breast cancer to live significantly longer, those that responded to treatment, according to data presented at AACR.
You may also be interested in...
Better than expected FDA labeling for rising star Perjeta in neoadjuvant (before surgery) and adjuvant (after surgery) breast cancer could boost sales greatly beyond expectations, some analysts say.
I-SPY2 study shows promising efficacy for PD-1 inhibitor Keytruda in combination with chemo in high-risk breast cancer – including a tripling of response rate in triple-negative breast cancer – but also raises red flag on immune-mediated adverse events in early-stage patients.
COVID-19 disruptions, less favorable currency and the shadow of drug price reform could mean more headwinds for pharma during this S&E period after a strong Q2.